Aurexis®
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus Bacteremia
Conditions
Staphylococcus Aureus Bacteremia
Trial Timeline
— → Feb 1, 2005
NCT ID
NCT00198302About Aurexis®
Aurexis® is a phase 2 stage product being developed by Bristol Myers Squibb for Staphylococcus Aureus Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT00198302. Target conditions include Staphylococcus Aureus Bacteremia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00198302 | Phase 2 | Completed |
Competing Products
12 competing products in Staphylococcus Aureus Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 77 |
| AZD7760 | AstraZeneca | Phase 1/2 | 41 |
| V710 + Placebo | Merck | Phase 2/3 | 65 |
| Daptomycin | Merck | Phase 2 | 52 |
| Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) | Merck | Phase 2 | 52 |
| Imipenem/cilastatin | Pfizer | Approved | 84 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| Aurexis® (tefibazumab) | Bristol Myers Squibb | Phase 2 | 51 |
| blood samples + nasal swabs | Sanofi | Pre-clinical | 22 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |